89bio, Inc.

Following GSK’s $1.2bn acquisition of privately held Boston Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) candidate efimosfermin on 14 May, the industry is wondering what re

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

GSK believes it has a potential best-in-class asset in steatotic liver disease after paying $1.2bn upfront to acquire efimosfermin from Boston Pharmaceuticals. Efimosfermin is a once-monthly fibroblas

AIM-NASH, the first artificial intelligence (AI)-based pathology tool to be qualified by the European Medicines Agency for assessing drug candidates for metabolic dysfunction-associated steatohepatiti